Starget Pharma Secures $18M Series A, Partners CMIT
Analysis based on 9 articles · First reported Feb 18, 2026 · Last updated Feb 18, 2026
The successful Series A financing for Starget Pharma, coupled with its collaboration with Center for Molecular Imaging and Therapy, is expected to positively impact the biotechnology and pharmaceutical sectors by accelerating the development of next-generation cancer therapies. This event also highlights United States===Louisiana's growing role in life sciences innovation, potentially attracting further investment and fostering economic growth in the region.
Starget Pharma Inc, a clinical-stage radiopharmaceutical company, announced the closing of an $18 million Series A financing round. This funding will support the advancement of its pipeline, including its lead SSTR3-targeted theranostic pair for sarcoma, neuroendocrine tumors, and malignant melanoma, and expand its U.S. translational and manufacturing capabilities. The financing round saw participation from United States===Louisiana Economic Development's Louisiana Growth Fund, Cancer Focus Fund, Biomedical Research Foundation of Northwest Louisiana, and Ilex Medical. Concurrently, Starget Pharma established a strategic collaboration with the Center for Molecular Imaging and Therapy (CMIT), a subsidiary of Biomedical Research Foundation of Northwest Louisiana. This partnership will leverage CMIT's integrated infrastructure for molecular imaging, radiochemistry, preclinical and clinical research, and radiopharmaceutical manufacturing to accelerate the development of AI-selected candidates. The collaboration aligns with United States===Louisiana's economic development strategy to attract and scale high-growth, technology-enabled companies in the life sciences sector.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard